SALT LAKE CITY, UT and CARROS, FRANCE / ACCESSWIRE / January 12, 2021 / SymbioCellTech, LLC (SCT), a biotechnology company in Salt Lake City, pioneering stem cell therapy for diabetes, today announced they have entered into an option agreement with Virbac (VIRP), the world's sixth-largest veterinarian pharmaceutical group to co-develop and commercialize their proprietary "Neo-Islet" cellular therapy to treat animals suffering from insulin-dependent diabetes. Type-1 Diabetes Mellitus (T1DM) is a disease in which the islet cells of the pancreas fail to produce the essential hormone, insulin.
Recent Comments